SELLAS Life Sciences Prices $150M Offering at $13 After 156% Phase 3 Rally
SELLAS Life Sciences priced a $150M stock offering at $13.00, a 27.6% discount to Wednesday's close, sending shares tumbling 20% premarket on dilution fears.

SELLAS Life Sciences Group priced a $150 million underwritten follow-on offering at $13.00 per share overnight, triggering a sharp premarket decline of roughly 20% on Thursday, November 19, 2026. The capital raise forces investors to weigh immediate equity dilution against the clinical breakthrough of its leukemia candidate following a 156% rally earlier this week.
What happened
Overnight into Thursday, SELLAS Life Sciences (Nasdaq: SLS) announced the pricing of 11,538,462 common shares at $13.00 each, aiming to raise $150.0 million in gross proceeds. The deal price marks a steep 27.6% discount to Wednesday’s closing price of $17.95. Joint book-running managers J.P. Morgan and TD Cowen received a 30-day option to buy up to an additional 1,730,769 shares, which could add $22.5 million.
The pricing abruptly halted momentum after SELLAS shares surged 156% following positive topline results from its pivotal Phase 3 REGAL trial for galinpepimut-S (GPS) in acute myeloid leukemia (AML). Ahead of Thursday's market open, SLS dropped about 20% to trade near $14.45.
Why it matters
Biotech companies rarely pass up the opportunity to tap capital markets after major clinical triumphs, and SELLAS followed that classic playbook. While the trial proved clinically potent—demonstrating a 41% reduction in the risk of death and extending median survival to 24.0 months—bringing a novel cancer therapy through regulatory approval requires substantial capital.
For retail shareholders who bought near Wednesday’s highs, the steep discount to institutional buyers hurts. Yet from a fundamental perspective, reading the balance sheet reveals why management acted decisively. Adding $150 million to the $134.7 million in cash SELLAS reported at the end of September removes going-concern risk and finances Biologics License Application (BLA) preparations. Management secured funding on strong terms relative to where the stock traded prior to the trial readout, even if short-term sentiment suffered.
What to watch next
- Offering closing: The transaction is scheduled to close on Friday, November 20, 2026, subject to customary conditions.
- Greenshoe execution: Whether underwriters exercise their option for 1.73 million additional shares within 30 days.
- FDA timeline: Pre-BLA meeting scheduling and regulatory guidance for GPS in AML maintenance therapy.
- Commercialization strategy: Potential regional partnerships or direct sales force investments in early 2027.
Sources (3)
This analysis is for information only and is not investment advice. Prices and figures as of publication.